Table 2.
Summary of baseline characteristics and outcomes of different analyses.
| Outcomes | Stage | Included studies | Baseline (WMD and 95% CI) |
Effect and 95% CI | |
|---|---|---|---|---|---|
| Age (year) | Tumour size (cm) | ||||
| Operative time | T1b | [29,30,33] | −0.61 (−2.36, 1.15) | −0.31 (−0.65, 0.04) | WMD –3.98 (−14.99, 7.02) |
| Estimated blood loss | T1b | [29,30] | −0.43 (−2.43, 1.57) | −0.19 (−0.56, 0.19) | WMD –16.47 (−68.06, 35.13) |
| Postoperative complications | T1b | [20,28,30,33] | −2.21 (−4.34, −0.08) | −0.33 (−0.66, 0.01) | RR 1.32 (0.95, 1.84) |
| Transfusion | T1b | [20,30] | −2.19 (−5.72, 1.34) | −0.13 (−0.51, 0.24) | RR 1.10 (0.69, 1.78) |
| Postoperative renal function | T1b | [20,26,30,31] | −3.24 (−6.43, −0.06) | −0.25 (−0.51, 0.01) | WMD 14.77 (11.65, 17.89) |
| Decline in renal function | T1b | [20,21,31] | −5.71 (−8.20, −3.21) | −0.65 (−0.80, −0.50) | WMD −6.60 (−12.85, −0.35) |
| Onset of CKD | T1b | [21,28,30,31] | −4.84 (−8.87, −0.82) | −0.39 (−0.81, 0.03) | RR 0.38 (0.19, 0.76) |
| Progression | T1b | [27,32] | NAa | NAa | HR 0.70 (0.40, 1.24) |
| Cancer-specific mortality | T1b | [22,25,26,30,[32], [33], [34]] | NAa | NAa | HR 0.91 (0.66, 1.26) |
| All-cause mortality | T1b | [22,26,[32], [33], [34]] | NAa | NAa | HR 1.01 (0.81, 1.26) |
WMD, weighted mean difference; CI, confidence interval; RR, risk ratio; HR, Hazard ratio; NA, not applicable; CKD, chronic kidney disease; RR, risk ratio.
a
Baseline differences for oncological outcomes were not showed in this table, as HRs were adjusted with ages and tumour sizes in included studies.